… that LRRK2 interacts with ribosomes, cellular protein factories. We then investigated whether LRRK2 changes the way … collect blood from people with one of the diseases similar to Parkinson's and from people with Alzheimer's disease and use these samples for comparison. From these blood samples, we will extract cells …

… NY — The Michael J. Fox Foundation for Parkinson’s Research today announced approximately $3.7 million in total funding … for continuous delivery of levodopa and conduct initial testing in human subjects. Continuous dopamine delivery … Unmet Needs Three projects reflect the Foundation’s commitment to drive research into “dopamine non-responsive” …

… are selectively eliminated in Parkinson’s disease (PD). To assess this protective activity, we exposed … doses of CNM-Au8 or a placebo, and we will then monitor and compare their behavior, metabolite levels, and the survival … on Diagnosis/Treatment of Parkinson’s Disease:  By targeting metabolic reactions in neurons, CNM-Au8 provides a …

… On July 2, 2024, President Biden signed the National Plan to End Parkinson’s Act into law! Please thank your members of Congress for passing …

… Study Rationale:  Both environmental and genetic factors are believed to be involved in Parkinson’s disease … the development of new policies to regulate use of these compounds. Study Design:  We will use stem cell lines to … induce PD-relevant phenotypes will allow us to investigate how environmental exposures contribute to the pathology of …

… U.S. regulatory agency recognizes potential of alpha-synuclein seed amplification assay (αSyn-SAA) to accelerate clear outcomes in drugmakers’ trials following multi-stakeholder … Heralded as “the study that’s changing everything” about how Parkinson’s is diagnosed, managed and treated, PPMI and …